Amman, Jordan – November 2019 –In a joint collaboration, Biolab, a regional pioneer in the field of medical diagnostics and laboratory testing,  and Roche – inpartnership with Foundation Medicine Inc. (two world leading companies in pharmaceuticals and molecular information), –launcheda new and unique service that provides cancer patients with a more comprehensive picture of cancer tumors. With thenewComprehensive Genomic Profiling (CGP)test,cancer patients diagnosed with certain genomic abnormalities and metastatic solid tumors, will be given the chance to explore a whole new range of possibilities based on one comprehensive test.This service is envisioned to transform cancer care and improve patient’s lives.

A single CGP test can provide a complete picture of a cancer tumor by searching for multiple mutations in a large number of cancer-related genes. It then matches them with relevant targeted therapies, immunotherapies and clinical trials to help guide personalized treatment decisions.

Biolab Founder and CEO, Dr. Abdelnour emphasized the importance of this advanced and unique service saying: “The advancement of patient care will always be Biolab’s ultimate goal.Testing is the first step in the treatment journey of cancer patients, therefore, Biolab and Roche are joining forces to increase the chances for better treatment options, which, if succeeds, will transform cancer care and improve patients’ lives. BiolabHistopathology Department will play a key role in the comprehensive diagnosis of cancer tumor samples and will work hand in hand with Roche to report with a more cohesive approach to the patients’ doctor.”

The process of this test starts with a biopsy sample that is sent to Biolab’s Histopathology Department to evaluate the quality of this biopsyand formulate a new histopathology report and diagnosis by their Histopathology Department if neededbefore transporting the samples.Biolab will then transport the samples to Foundation Medicine’s laboratory, where it will be analyzed and examined for genomic alterations. Foundation Medicinewill then send the patient’s doctor a detailed report with information about the tumor’s genomic makeup, potential treatment options, and clinical trials. The patient and his/her doctor can then evaluate the results and determine the medical steps to take.

The genomic profile of each patient’s tumour is unique – and may hold the key to treating their cancer. That’s where testing can make the difference. Testing is the first step in the journey of every person with cancer. Every cancer is unique and the more CGP provides a comprehensive look andthe role of mutations in cancer-related genes, the more doctorsare empowered to treat their cancer patients more precisely and individually.

As a regional pioneer in the field of medical diagnostics and laboratory testing, Biolab provides an extensive portfolio of more than 700 diagnostic services, catering to individuals, physicians, hospitals, and other laboratories across the Middle East. In Jordan, Biolab operates a total of 18 branches, in key locations throughout Amman – such as Al Khalidi Street, Fifth Circle, Hay Al-Yasmeen, Marj Al-Hamam, Khalda, City Mall, Bayader-Wadi Seer, Shmeisani, Third Circle, Tila’ Al Ali, Jubeiha, Moqabalein, in addition to locations outside the capital Amman namely Fuheis and Irbid. Biolab offers its patients and customers the convenience of receiving their test results online at www.biolab.jo and via its advanced mobile application.

Along with its ISO 15189 certification provided by the Jordanian Accreditation System (JAS) for quality health services, Biolab’s medical diagnostic services are accredited by the Jordanian Ministry of Health, the Joint Commission International (JCI), and the College of American Pathologists (CAP). Biolab has recently obtained accreditation from the Health Care Accreditation Council (HCAC) and is now the only stand-alone laboratory in the region that is endorsed by four international accreditation bodies.